Literature DB >> 19225075

Differences in tuberculin reactivity as determined in a veterans administration employee health screening program.

Sanjay R Mehta1, Cathy MacGruder, David Looney, Scott Johns, Davey M Smith.   

Abstract

In response to a difference in pricing, the San Diego Veterans Administration Medical Center changed its tuberculin preparation from Tubersol to Aplisol in the fall of 2006. Following the change, an increased number of employee skin test conversions was noted. Employee tuberculin skin test converters from 2006 were screened with the QuantiFERON Gold (QFT-G) gamma interferon release assay. Those employees who tested negative by QFT-G were asked to repeat their skin test with both Tubersol and Aplisol tuberculin preparations. Of the new purified protein derivative converters, 12 of 14 returned for repeat testing with QFT-G, and the assay was negative for 83% (10/12), positive for 8% (1/12), and indeterminate for 8% (1/12) of the individuals. Nine of the individuals who were QFT-G negative agreed to repeat skin testing with both tuberculin preparations, and 7/8 (87.5%) demonstrated reactivity with the Aplisol preparation, while 0/8 (0%) reacted to the Tubersol preparation. A change from Tubersol to Aplisol resulted in elevated tuberculin skin test conversion rates that may be due to false-positive reactions. The differences in skin test reactivity between preparations support CDC guidelines that recommend that institutions should not change tuberculin preparations, as doing so may falsely increase the number of positive reactions.

Mesh:

Year:  2009        PMID: 19225075      PMCID: PMC2668276          DOI: 10.1128/CVI.00375-08

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  12 in total

1.  False-positive tuberculin skin test results among health care workers.

Authors:  H M Blumberg; N White; P Parrott; W Gordon; M Hunter; S Ray
Journal:  JAMA       Date:  2000-06-07       Impact factor: 56.272

Review 2.  Evolution and current use of the tuberculin test.

Authors:  Elsie Lee; Robert S Holzman
Journal:  Clin Infect Dis       Date:  2001-12-13       Impact factor: 9.079

3.  Increase in tuberculin skin test converters among health care workers after a change from Tubersol to Aplisol.

Authors:  Kari A Gillenwater; Sandra C Sapp; Kim Pearce; George K Siberry
Journal:  Am J Infect Control       Date:  2006-12       Impact factor: 2.918

4.  Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection.

Authors:  Giovanni Ferrara; Monica Losi; Marisa Meacci; Barbara Meccugni; Roberto Piro; Pietro Roversi; Barbara Maria Bergamini; Roberto D'Amico; Patrizia Marchegiano; Fabio Rumpianesi; Leonardo M Fabbri; Luca Richeldi
Journal:  Am J Respir Crit Care Med       Date:  2005-06-16       Impact factor: 21.405

5.  Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States.

Authors:  Gerald H Mazurek; John Jereb; Phillip Lobue; Michael F Iademarco; Beverly Metchock; Andrew Vernon
Journal:  MMWR Recomm Rep       Date:  2005-12-16

6.  Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005.

Authors:  Paul A Jensen; Lauren A Lambert; Michael F Iademarco; Renee Ridzon
Journal:  MMWR Recomm Rep       Date:  2005-12-30

7.  Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country.

Authors:  Young Ae Kang; Hye Won Lee; Ho Il Yoon; BeLong Cho; Sung Koo Han; Young-Soo Shim; Jae-Joon Yim
Journal:  JAMA       Date:  2005-06-08       Impact factor: 56.272

8.  Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis.

Authors:  Roland Diel; Robert Loddenkemper; Karen Meywald-Walter; Stefan Niemann; Albert Nienhaus
Journal:  Am J Respir Crit Care Med       Date:  2008-02-14       Impact factor: 21.405

9.  Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens.

Authors:  Toru Mori; Mitsunori Sakatani; Fumio Yamagishi; Tetsuya Takashima; Yoshiko Kawabe; Keiji Nagao; Eriko Shigeto; Nobuyuki Harada; Satoshi Mitarai; Masaji Okada; Katsuhiro Suzuki; Yoshikazu Inoue; Kazunari Tsuyuguchi; Yuka Sasaki; Gerald H Mazurek; Izuo Tsuyuguchi
Journal:  Am J Respir Crit Care Med       Date:  2004-04-01       Impact factor: 21.405

10.  Comparable specificity of 2 commercial tuberculin reagents in persons at low risk for tuberculous infection.

Authors:  M E Villarino; W Burman; Y C Wang; L Lundergan; A Catanzaro; N Bock; C Jones; C Nolan
Journal:  JAMA       Date:  1999-01-13       Impact factor: 56.272

View more
  5 in total

1.  Changes in tuberculin skin test positivity over 20 years in periurban shantytowns in Lima, Peru.

Authors:  Leonardo Martinez; Alyssa Arman; Nathan Haveman; Ashley Lundgren; Lilia Cabrera; Carlton A Evans; Tom F Pelly; Mayuko Saito; David Callacondo; Richard Oberhelman; Gisela Collazo; Andrés M Carnero; Robert H Gilman
Journal:  Am J Trop Med Hyg       Date:  2013-07-22       Impact factor: 2.345

2.  Diagnosis and treatment of latent tuberculosis infection: an update.

Authors:  Anna K Person; April C Pettit; Timothy R Sterling
Journal:  Curr Respir Care Rep       Date:  2013-12

Review 3.  Purified protein derivatives of tuberculin--past, present, and future.

Authors:  Hongliang Yang; Nicole A Kruh-Garcia; Karen M Dobos
Journal:  FEMS Immunol Med Microbiol       Date:  2012-08-01

4.  The single recombinant M. tuberculosis protein DPPD provides enhanced performance of skin testing among HIV-infected tuberculosis patients.

Authors:  Roberto Badaro; Bruna A S Machado; Malcolm S Duthie; C A Araujo-Neto; D Pedral-Sampaio; Maria Nakatani; Steven G Reed
Journal:  AMB Express       Date:  2020-07-31       Impact factor: 3.298

Review 5.  Skin tests for the detection of Mycobacterial infections: achievements, current perspectives, and implications for other diseases.

Authors:  Malcolm S Duthie; Steven G Reed
Journal:  Appl Microbiol Biotechnol       Date:  2021-01-04       Impact factor: 4.813

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.